Olema Pharmaceuticals (OLMA) Competitors

Olema Pharmaceuticals (NASDAQ:OLMA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Does the MarketBeat Community prefer OLMA or AMPH?

Amphastar Pharmaceuticals received 354 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. However, 72.22% of users gave Olema Pharmaceuticals an outperform vote while only 65.83% of users gave Amphastar Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Olema Pharmaceuticals	Outperform Votes 39 72.22%	Underperform Votes 15 27.78%
Amphastar Pharmaceuticals	Outperform Votes 393 65.83%	Underperform Votes 204 34.17%

Do institutionals and insiders hold more shares of OLMA or AMPH?

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 16.4% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 27.5% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is OLMA or AMPH more profitable?

Amphastar Pharmaceuticals has a net margin of 21.80% compared to Olema Pharmaceuticals' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-53.56%	-47.86%
Amphastar Pharmaceuticals	21.80%	26.44%	11.89%

Which has preferable valuation & earnings, OLMA or AMPH?

Amphastar Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$96.65M	-$2.01	-2.04
Amphastar Pharmaceuticals	$730.66M	1.71	$137.54M	$2.76	9.58

Which has more risk and volatility, OLMA or AMPH?

Olema Pharmaceuticals has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Does the media favor OLMA or AMPH?

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 8 mentions for Amphastar Pharmaceuticals and 3 mentions for Olema Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.93 beat Olema Pharmaceuticals' score of -0.03 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend OLMA or AMPH?

Olema Pharmaceuticals currently has a consensus target price of $24.50, suggesting a potential upside of 496.11%. Amphastar Pharmaceuticals has a consensus target price of $32.33, suggesting a potential upside of 22.34%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amphastar Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Amphastar Pharmaceuticals beats Olema Pharmaceuticals on 11 of the 17 factors compared between the two stocks.